Lenacapavir has the potential to reach millions — and the momentum is building. Using the current oral PrEP market as a baseline, this graphic estimates what demand for LEN could look like through 2028 and shows how current donor commitments stack up against that opportunity.
Was this content helpful?
Tell us how we can improve the content.
Was this content helpful?
Thank you for your feedback!